Add to Favourites
To login click here
IGC Pharma, Inc. has added Pablo Arbelaez, Ph.D., an expert in artificial intelligence, to support the development of their lead therapeutic candidate for Alzheimer’s disease. Dr. Arbelaez will utilize AI to analyze disease signatures and identify patients who are most likely to respond to treatment. He will also advise on the development of deep learning algorithms to predict the progression of physiological and psychological variables in patients enrolled in the Phase 2 clinical trial.